Business Context and Reporting Period
This Form 8-K Current Report was filed by Alzamend Neuro, Inc. (ALZN) on August 7, 2023. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Atlanta, Georgia. The report addresses a critical corporate governance event regarding the continued listing of its common stock on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or margin data for the reporting period. However, it references a specific financial threshold failure: the Company does not meet Nasdaq's $5 million minimum stockholders' equity initial listing requirement, which disqualifies it from a second compliance period.
Material Changes and Events
- Delisting Notice: On August 1, 2023, Nasdaq notified the Company that it failed to regain compliance with Listing Rule 5550(a)(2) regarding the minimum bid price of $1.00 per share over a 30-day period.
- Compliance Failure: The Company was originally given 180 days (until July 31, 2023) to regain compliance but failed to do so.
- Eligibility for Extension: The Company is ineligible for a second 180-day compliance period because it fails to meet the $5 million minimum stockholders' equity requirement.
- Proposed Suspension: Absent an appeal, the Company's stock was scheduled to be suspended and delisted from Nasdaq on August 10, 2023.
Outlook, Management Commentary, and Risks
Appeal Status: The Company has submitted an appeal to a Nasdaq Hearings Panel. This action stays the suspension of trading and the filing of the Form 25-NSE pending the Panel's decision.
Current Trading Status: As of the filing date, the Company's common stock continues to trade on The Nasdaq Capital Market under the symbol "ALZN."
Next Steps: A hearing before the Hearings Panel has been scheduled for October 12, 2023. The outcome of this hearing will determine whether the stock remains listed or is delisted.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel scheduled for October 12, 2023.
- Confirm the current trading status of ALZN shares following the appeal decision.
- Review the Company's stockholders' equity position to understand the barrier to regaining listing eligibility.
- Monitor for any subsequent filings (e.g., Form 25-NSE) if the appeal is unsuccessful.